Testing Data
(Sample(30 mug of whole cell lysate)A:293T B:A431 12% SDS PAGE diluted at 1:200)
Rabbit anti-Human EIF4A2 Polyclonal Antibody | anti-EIF4A2 antibody
EIF4A2 Antibody
Testing Data
(Sample(30 mug of whole cell lysate)A:293T B:A431 12% SDS PAGE diluted at 1:200)
Testing Data
(Sample(30 mug of whole cell lysate)A:293T B:A431 12% SDS PAGE diluted at 1:200)
NCBI and Uniprot Product Information
Uniprot Description
EIF4A2: ATP-dependent RNA helicase which is a subunit of the eIF4F complex involved in cap recognition and is required for mRNA binding to ribosome. In the current model of translation initiation, eIF4A unwinds RNA secondary structures in the 5'-UTR of mRNAs which is necessary to allow efficient binding of the small ribosomal subunit, and subsequent scanning for the initiator codon. Belongs to the DEAD box helicase family. eIF4A subfamily. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Helicase; Translation initiation; Translation; RNA-binding; EC 3.6.4.13
Chromosomal Location of Human Ortholog: 3q28
Cellular Component: perinuclear region of cytoplasm; eukaryotic translation initiation factor 4F complex; cytosol
Molecular Function: protein binding; translation initiation factor activity; ATPase activity; helicase activity; ATP binding
Biological Process: poly(A) tail shortening; cellular protein metabolic process; viral reproduction; translation; cytokine and chemokine mediated signaling pathway; translational initiation; gene expression; regulation of translational initiation; mRNA catabolic process, deadenylation-dependent decay
Research Articles on EIF4A2
Similar Products
Product Notes
The EIF4A2 eif4a2 (Catalog #AAA9411515) is an Antibody produced from Rabbit and is intended for research purposes only. The product is available for immediate purchase. The EIF4A2 Antibody reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's EIF4A2 can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB). Western blotting: 1:100-1:1000. Researchers should empirically determine the suitability of the EIF4A2 eif4a2 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "EIF4A2, Polyclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
